Rentschler Biopharma SE

Dr. Günter Stempfer appointed Site Head Laupheim for Rentschler Biopharma

Rentschler Biopharma SE / Key word(s): Personnel


04.12.2023 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---

Laupheim, Germany, December 4, 2023 – Rentschler Biopharma SE, a leading contract development and manufacturing organization (CDMO) for biopharmaceuticals, including Advanced Therapy Medicinal Products (ATMPs), announced today that Dr. Günter Stempfer has been appointed Site Head of the company’s facility in Laupheim, Germany, effective December 1, 2023. In this role, he is heading the Site Leadership Team in Laupheim and is part of the Global Leadership Team. At the Laupheim site, Dr. Stempfer is responsible for continuously identifying opportunities for improvement, reliably ensuring the development and production of complex biopharmaceuticals for clients and implementing innovative changes at the site in coordination with the Extended Executive Team. He reports to Chief Operating Officer (COO) Christiane Bardroff. Christiane Bardroff, COO of Rentschler Biopharma, said: “The appointment of Günter Stempfer as Site Head for Laupheim is an optimal solution. He has a deep knowledge of this production site and a proven track record of working effectively and successfully with the local team. With Günter Stempfer’s strong leadership and exceptional capabilities, we will ensure operational excellence at our headquarter’s site, in the interest of sustainability and patient care”. Dr. Stempfer joined Rentschler Biopharma on January 1, 2022, as Head of Global Strategic Development. Prior to that, he had advised the company in the area of production and led daily operations at the Laupheim site in close collaboration with the Company Leadership Team since the summer of 2021. Dr. Stempfer brings more than 25 years of experience in the biopharmaceutical industry. He has held various leadership positions, including Site Head at Sandoz in Kundl, Austria; Project Director at Novartis in Huningue, France; and Director Global TechOps at Polpharma in Poland, and is a recognized expert in development and production. "Throughout my various roles at Rentschler Biopharma, my primary objective has always remained the same: the efficient, accurate, and timely delivery, also for complex development and production tasks, to enable our clients to provide effective medicines for seriously ill patients. The highly competent team in Laupheim shares this same commitment, and I look forward to our continued collaboration. At the same time, I will utilize my strong ties to our Stevenage and Milford sites to further strengthen collaboration and exchange across sites," Dr. Günter Stempfer commented.
  About Rentschler Biopharma SE Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals, including adeno-associated virus (AAV) gene therapies, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,400 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. Rentschler ATMP Ltd., located in Stevenage, UK, is dedicated to cell and gene therapies. For further information, please visit www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn and Facebook. Contact: Rentschler Biopharma SE
Dr. Latika Bhonsle-Deeng
Senior Director Corporate Communication
Phone: [phone]
[e-mail] Media inquiries:

MC Services AG Eva Bauer Phone: [phone] [e-mail]

U.S. Laurie Doyle Phone: [phone]

For high-resolution images, please contact [e-mail]

---

04.12.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---

1787929  04.12.2023 CET/CEST